Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

Please sign in to follow a disease.

← Back to home

Onkure, Inc.

Clinical trials sponsored by Onkure, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug targets Hard-to-Treat cancers with PI3K mutation Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 1

New drug targets Hard-to-Treat cancers with PI3K mutation

Disease control Ongoing

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

Phase 1 • Sponsor: OnKure, Inc. • Aim: Disease control

Last updated Jul 08, 2026 00:00 UTC